A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/9/12/1343/19481595/9-12-1343.pdf
Reference15 articles.
1. Registrations 1987 England and Wales;Office of Population Censuses and Surveys Cancer Statistics,1988
2. Activity of gemcitabine in the treatment of patients with non-small-cell lung cancer: A multicenter phase II study;Yokoyama;Anti-Cancer Drugs,1997
3. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study;Anderson;J Clin Oncol,1994
4. Activity of gemcitabine in patients with non-small-cell lung cancer: A multicentre, extended phase II study;Gatzemeier;Eur J Cancer,1996
5. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study;Pollera;Ann Oncol,1994
Cited by 119 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The efficacy of tyrosine kinase inhibitors combined with chemotherapy for recurrent ovarian cancer: a systematic review and network meta-analysis;Minerva Biotechnology and Biomolecular Research;2024-05
2. Treatment options for recurrent platinum-resistant ovarian cancer: A systematic review and Bayesian network meta-analysis based on RCTs;Frontiers in Oncology;2023-04-11
3. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update;International Journal of Gynecology & Obstetrics;2021-10
4. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer;Nature Communications;2021-09-22
5. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma;Gynecologic Oncology;2020-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3